/
Nutriband Inc. (the Company , Nutriband , we or us ), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products.
The business is unprofitable at the operating level (-408.41% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 4.8% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -94.72% to -97.74%, capital efficiency is deteriorating. Negative free cash flow of -$5M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$2M
▼ -4.8% YoY
Net Income (TTM)
-$8M
▲ +21.5% YoY
Op. Margin
-408.41%
▲ +72.3pp YoY
ROIC
-97.74%
▼ -3.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▼ -8.9% YoY
Op. Cash Flow (TTM)
-$5M
▼ -11.0% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$5M
5Y CAGR: +16.6%
Continue Research